Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial

Hodgkin Lymphoma Clinical Trial

— FIL-RougeBIO  

Official title:

Circulating Tumor DNA Genotyping for Biological Monitoring of Patients With Advanced-stage Classical HL Receiving Upfront ABVD-based Chemotherapy. An Ancillary Study to the FIL-Rouge Phase III Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05066555
• Other study ID #: FIL-RougeBIO
• Status: Active, not recruiting
• Start date: April 8, 2020
• Est. completion date: May 2024

Study information

• Verified date: December 2023
• Source: Fondazione Italiana Linfomi - ETS
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma, ABVD-based upfront treatment in 19 centers in Italy part of Fondazione Italiana Linfomi.

Description:

The FIL-Rouge design provides an ideal environment for validating the liquid biopsy in Classical Hodgkin lymphoma (cHL), since one arm of the study will utilize a PET/CT-adapted strategy (Positron Emission Tomography/Computed Tomography)for treatment, while the second arm will be devoid of any PET/CT-adaptation of therapy. Also, estimating prospectively differences in residual disease between the two study arms of the FIL-Rouge will provide an important biologic tool to validate the concept of dose-intensification within the ABVD therapeutic platform.

This study aims at the prospective validation of the concept of the liquid biopsy as a biomarker for disease response assessment in cHL. The patients enrolled in the FIL-Rouge clinical trial at the centers participating in this study and consenting to the biological study FIL-RougeBIO will be considered for this study. After providing written informed consent, relevant patients will be evaluated for detecting cancer gene mutations in ctDNA (Circulating Tumor DNA) for measuring residual disease. All clinical data useful for data analyses of this study will derive from the FIL-Rouge clinical trial.

Given the non-interventional design of the study, project participants will not have immediate potential benefits.The enrollment in FIL-RougeBIO will parallel the original protocol until reaching the 500 programmed patients. The results of this study could benefit future patients with the same condition.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: May 2024
• Est. primary completion date: November 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria: FIL ROUGE INCLUSION CRITERIA

• Histologically confirmed classical HL

• Previously untreated disease

• Age 18-60 years

• Ann Arbor stage IIB with extranodal involvement and/or bulk, III and IV

• At least one target PET-avid bidimensionally assessable lesion

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2

• Adequate organ and marrow function as defined below:

• Absolute neutrophil count >1,0 x109/L, platelets >75 x109/L

• Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome

• Aspartate Transaminase and Alanine Transaminase (AST/ALT) <3 X institutional Upper Limits of Normality (ULN)

• Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2

• Females of childbearing must have a negative pregnancy test under medical supervision even if patients had been using effective contraception

• Life expectancy > 6 months

• Able to adhere to the study visit schedule and other protocol requirements

• Signed (or legally acceptable representatives must sign) informed consent indicating that patients understand the purpose of and procedures required for the study and are willing to participate in the study.

• Access to PET-CT (Positron Emission Tomography/Computed Tomography) scans facilities qualified by FIL

Exclusion Criteria: FIL ROUGE EXCLUSION CRITERIA

• Nodular Lymphocyte Predominant HL

• Ann Arbor stage IIB without extranodal involvement and/or mediastinal bulky

• Prior chemotherapy or radiation therapy

• Pregnant or lactating females

• Known hypertension, cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or left ventricular ejection fraction (LVEF) =50% at echocardiography.

• Abnormal QTc interval prolonged (>450 msec in males; >470 msec in women)

• Diffusion lung capacity for CO (DLCO)and/or Forced expiratory volume in the 1st second (FEV1) tests <50% of predicted not due to mediastinal compression or parenchymal lymphoma

• Known cerebral or meningeal disease (HL or any other etiology)

• Prior history of malignancies unless the patient has been free of the disease for five years. Exceptions include the following: basal cells carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast and prostate cancer with the TNM stage of T1a or T1b

• Uncontrolled infectious disease

• Human immunodeficiency virus (HIV) positivity or active infectious A, B or C hepatitis. HBsAg-negative patients with anti-HBc (Hepatitis B core) antibody and can be enrolled provided that Hepatitis B Virus (HBV)-DNA are negative and that antiviral treatment with nucleos(t)ide analogs is provided (Lamivudine)

• Uncompensated diabetes

• Refusal of adequate contraception

• Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment.

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico	Avellino
Italy	IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia	Bari
Italy	ASST Spedali Civili di Brescia - Ematologia	Brescia
Italy	ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia	Milano
Italy	Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - UOC Ematologia Oncologica	Napoli
Italy	Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia	Pagani
Italy	A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia	Palermo
Italy	IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia	Pavia
Italy	Ospedale S. Maria della Misericordia - Ematologia	Perugia
Italy	P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi	Pescara
Italy	Ospedale degli Infermi di Rimini - U.O. di Ematologia	Rimini
Italy	Istituto Clinico Humanitas - U.O. Ematologia	Rozzano
Italy	A.O.U. Citta della Salute e della Scienza di Torino - S.C.Ematologia	Torino

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Italiana Linfomi - ETS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response Rate (CRR)	Complete Response Rate (CRR) is defined as the proportion of patients achieving a Complete Remission (CR) at the end of treatment;	The endpoint will be assessed from the beginning of the study up to 76 months
Secondary	Diagnostic accuracy of Circulating tumor DNA (ctDNA) analysis versus interim PET/CT (Positron Emission Tomography/Computed Tomography)	Diagnostic accuracy of Circulating tumor DNA (ctDNA) analysis versus interim PET/CT (sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratios accuracy); The endpoint will be evaluated through specific timepoints.	The endpoint will be assessed from the beginning of the study up to 76 months
Secondary	Progression Free Survival (PFS) with at least three years of follow up	PFS is defined as the interval elapsing from randomization until lymphoma progression/relapse or death as a result of any cause.	The endpoint will be assessed from the beginning of the study up to 76 months